Replies to post #500355 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

Missling getting us into the CNPV is an important test for AVXL mgt. We are well positioned as most of the materials needed were already loaded for the EMA.

I am hopeful for our chances with the CNPV, despite widespread competition, simply because Alzheimer's Disease is certainly a top -- if the not top -- unaddressed public health priority facing this country. And blarcamesine is the best positioned current AD drug candidate in development with what would be a very popular daily pill, no significant risk approach.

The need is clear, the safety is high, the papers are largely ready, and the FDA can even get a peek at the EMA, knowing AVXL passed clock stop oine and maybe clock stop two soon. In fact they might know the EMA recommended approval, which would allow the FDA to get a very low risk candidate to speed through this program as it was already pre-vetted.

So it is very important for AVXL to do their best to get in. A test of Misslings management skills.

[rx7171]

My concern is big pharma has more lobbying power than this tiny biotech that ran its AD trial at sites outside of the US.